title: Pleuropulmonary fibrosis due to bromocriptine treatment for Parkinson's disease.
abstract: Pleuroplumonary fibrosis is an uncommon but potentially serious adverse effect of bromocriptine used in the treatment of Parkinson's disease. Two cases of this reaction, which occurred 12 months and 5 months respectively after commencing therapy are here reported. In both instances prompt clinical and radiological improvement occurred when bromocriptine intake was ceased. Fibrotic reactions to bromocriptine may be mediated by a serotonergic mechanism. Periodic monitoring of pulmonary symptoms is warranted in patients receiving bromocriptine treatment for Parkinson's disease.
authors: Department of Neurology, Repatriation General Hospital, Brisbane.
authors: D H
authors: DH
authors: Todman
authors: W A
authors: WA
authors: Oliver
authors: R L
authors: RL
authors: Edwards
mesh_terms: D000368:Aged; D001545:Benserazide / Q000627:therapeutic use; D001971:Bromocriptine / Q000009:adverse effects* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy*; D011658:Pulmonary Fibrosis / Q000139:chemically induced*; D012701:Serotonin / Q000378:metabolism
chemical_list: D012701:Serotonin; D001971:Bromocriptine; D007980:Levodopa; D001545:Benserazide